Novo Nordisk (NVO) said Thursday it will move its subcutaneous and oral amycretin candidate for weight management into phase 3 clinical development.
The phase 3 development of the GLP-1 candidate for adults with obesity is based on feedback from regulators on completed clinical trials, according to a statement.
The company said it plans to begin the phase 3 program in Q1 2026.
Shares were up 2.5% in recent trading.
Price: 80.85, Change: +2.12, Percent Change: +2.69
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.